AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21806769
Drug: Valsartan/Amlodipine/HCTZ 160/5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine/HCTZ 160/5/25 mg
Trial: 21806769
Drug: Losartan/HCTZ 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/HCTZ 100/25 mg
Trial: 21806769
Drug: Valsartan/Amlodipine/HCTZ 320/10/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine/HCTZ 320/10/25 mg (after titration)
Trial: 16930934
Drug: L-thyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine treatment for 6 months
Trial: 31300595
Drug: Dexamethasone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (5 mg)
Trial: 8496313
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA; 20 mg/day) with GnRH analog (leuprolide acetate; 1 mg/day, sc)
Trial: 31603012
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT4): oral dexamethasone 40 mg for days 1-4, oral cyclosporine A 2–3 mg/kg daily for 28 consecutive days, intravenous rituximab 100 mg for days 7, 14, 21, and 28
Trial: 31603012
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT4)
Trial: 30112726
Drug: DFN-11 (sumatriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-11 (sumatriptan injection, 3 mg)
Trial: 21144456
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with co-interventions (including NSAIDs or analgesics)
Trial: 19195455
Drug: Darunavir (DRV/r)
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir (DRV/r) 600/100 mg two times a day
Trial: 16606546
Drug: Nebulized furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized furosemide (10 mg/m2) plus nebulized salbutamol (0.15 mg/kg)
Trial: 16606546
Drug: Nebulized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized saline (placebo) plus nebulized salbutamol (0.15 mg/kg)
Trial: 12846772
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of iron sucrose administered intravenously over two hours
Trial: 12846772
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously over two hours
Trial: 1451726
Drug: MK-571 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (75 mg)
Trial: 1451726
Drug: MK-571 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (300 mg)
Trial: 1451726
Drug: MK-571 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (600 mg)
Trial: 1451726
Drug: MK-571 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (all doses)
Trial: 2698566
Drug: Gallopamil 50
RxNorm normalized name: gallopamil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 50 mg
Trial: 6391005
Drug: Gallopamil 50
RxNorm normalized name: gallopamil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 50 mg and Nifedipine 10 mg
Trial: 28557857
Drug: 5-mg melatonin
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg melatonin supplement
Trial: 27491280
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg alone
Trial: 27491280
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg alone
Trial: 27491280
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg plus Dapagliflozin 10 mg coadministered
Trial: 22479985
Drug: Combined orthodontic/regenerative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined orthodontic/regenerative therapy with immediate orthodontic tooth movement
Trial: 22479985
Drug: Combined orthodontic/regenerative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined orthodontic/regenerative therapy with delayed orthodontic tooth movement
Trial: 22479985
Drug: Regenerative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative therapy alone (control group)
Trial: 17609397
Drug: GHRP-2 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRP-2 (100 microg dose administered intravenously)
Trial: 11892709
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection of methylprednisoloneacetate and lidocaine (MP group)
Trial: 10780243
Drug: Ethanol (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.2, 0.4 or 0.8 g/kg)
Trial: 10780243
Drug: Triazolam (0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125, 0.25 or 0.5 mg)
Trial: 6167117
Drug: Aspirin dipyridamole
RxNorm normalized name: aspirin / dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin dipyridamole combination
Trial: 31810219
Drug: Rice with
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice with sugar solution preload (PSS+R)
Trial: 29957283
Drug: Task-oriented daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented daily physical activity (DPA) assessed using interviewer-administered recall questionnaire (DPA-R) in Cohort 1
Trial: 29957283
Drug: Task-oriented daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented daily physical activity (DPA) assessed using self-administered diary-format daily checklist (DPA-C) in Cohort 2
Trial: 26874291
Drug: Exposure based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure based treatment
Trial: 22760558
Drug: Almond-containing diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond-containing diet (42 g/d)
Trial: 22760558
Drug: Almond-containing diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond-containing diet (84 g/d)
Trial: 22760558
Drug: Controlled diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled diet (0 g/d)
Trial: 19896213
Drug: Olanzapine/fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/fluoxetine combination treatment
Trial: 15277171
Drug: Nutritional counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counseling to increase intake through diet and high-energy supplements
Trial: 7826222
Drug: Ozagrel (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozagrel (400 mg/day) for 4 weeks, then DSCG (8 mg/day) for 4 weeks
Trial: 7826222
Drug: DSCG (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSCG (8 mg/day) for 4 weeks, then Ozagrel (400 mg/day) for 4 weeks
Trial: 22289281
Drug: Esmolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (50 μg/kg/min)
Trial: 30129080
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen Therapy (HBOT) - 30 treatments of 100% oxygen at 2.4 ATA for 80 minutes
Trial: 30129080
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment - 30 'sham' treatments, initially pressurized to 1.2 ATA, then cycled between 1.05–1.2 ATA for eight minutes before settling at 1.05 ATA
Trial: 25592656
Drug: Levofloxacin inhalation
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin inhalation solution (APT-1026)
Trial: 24018268
Drug: Social Cognition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Cognition and Interaction Training (SCIT) plus treatment-as-usual
Trial: 24018268
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control group (treatment-as-usual only)
Trial: 21788905
Drug: Omocianine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omocianine (0.1 mg/kg)
Trial: 21788905
Drug: Omocianine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omocianine (all dose groups)
Trial: 7484983
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (diphenhydramine, 12.5 mg)
Trial: 7484983
Drug: Fluoxetine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine with detectable blood levels
Trial: 7484983
Drug: Fluoxetine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine with no detectable blood levels
Trial: 8648369
Drug: Epirubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 60 mg/m2
Trial: 2265137
Drug: Epirubicin 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 45 mg/m2 and Vindesine 3 mg/m2 on days 1 and 8 every 4 weeks
Trial: 538812
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of long-acting penicillin (Triplopen)
Trial: 30204244
Drug: Tick‐E‐Vac vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tick‐E‐Vac vaccine
Trial: 30204244
Drug: EnceVir vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EnceVir vaccine
Trial: 30204244
Drug: Tick‐E‐Vac and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tick‐E‐Vac and EnceVir vaccines
Trial: 28328712
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplementation (25 g)
Trial: 28328712
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (25 g)
Trial: 24383406
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Treatment of Insomnia (BBTI)
Trial: 17302587
Drug: EC‐MPS 1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS 1080 mg bid
Trial: 17302587
Drug: MMF 1500
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 1500 mg bid
Trial: 11256540
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus 25 mg i.v. of canrenoate (1 mg/hour for the first 72 hours and then orally 25 mg/day)
Trial: 8032582
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg and codeine 30 mg in one combination tablet
Trial: 8032582
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg and codeine 60 mg in one combination tablet
Trial: 8032582
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg and codeine 30 mg in two separate tablets
Trial: 8032582
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg and codeine 60 mg in two separate tablets
Trial: 2600323
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg every 12 hours for seven doses
Trial: 30804129
Drug: Gefitinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib at 250 mg/day
Trial: 30804129
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus bevacizumab at 15 mg/kg every 3 weeks
Trial: 26422724
Drug: Cigarettes containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes containing 2.4 mg of nicotine per gram of tobacco
Trial: 26422724
Drug: Cigarettes containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes containing 1.3 mg of nicotine per gram of tobacco
Trial: 26422724
Drug: Cigarettes containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes containing 0.4 mg of nicotine per gram of tobacco
Trial: 26422724
Drug: Cigarettes containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes containing 15.8 mg of nicotine per gram of tobacco
Trial: 26422724
Drug: Cigarettes containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes containing 5.2 mg of nicotine per gram of tobacco
Trial: 17519902
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (IV‐MO)
Trial: 15771319
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 60 mg once daily
Trial: 12714828
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (60-U/kg bolus and 12-U/kg/h infusion for 72 hours)
Trial: 12714828
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (not specified dosage)
Trial: 2659136
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose polyoestradiol phosphate (PEP) 160 mg
Trial: 2659136
Drug: Daily low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily low dose acetosalicylic acid (ASA) 75 mg
Trial: 28833832
Drug: EtG-based contingency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EtG-based contingency management (CM) intervention for alcohol abstinence and addiction treatment attendance for 12 weeks
Trial: 21228137
Drug: Intranasal measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal measles vaccine (Moraten)
Trial: 21228137
Drug: Subcutaneous measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous measles vaccine (Moraten)
Trial: 16723785
Drug: Pilsicainide (Pil)
RxNorm normalized name: Pilsicainide
DrugBank: Pilsicainide (DB12712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilsicainide (Pil) 150 mg/day
Trial: 16723785
Drug: Cibenzoline (Cib)
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (Cib) 300 mg/day
Trial: 11421998
Drug: Domperidone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (1 mg kg‐1)
Trial: 11421998
Drug: Sulpiride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (10 mg kg‐1)
Trial: 25549517
Drug: Intrusive force
RxNorm normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrusive force of 100 g delivered from mini-implants for 6 months
Trial: 20837952
Drug: Regimen 1A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 1A: Irinotecan 20 mg/m(2)/d intravenously for 5 days at weeks 1, 2, 4, and 5 with vincristine 1.5 mg/m(2) on day 1 of weeks 1, 2, 4, and 5
Trial: 20837952
Drug: Regimen 1B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 1B: Irinotecan 50 mg/m(2)/d intravenously for 5 days at weeks 1 and 4 with vincristine as in regimen 1A
Trial: 18443034
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 500 mg
Trial: 15983224
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg intravenously from ‐30 to ‐15 min) with GLP-1
Trial: 1440118
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 0.12% chlorhexidine gluconate (Peridex, Procter & Gamble)
Trial: 1440118
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL placebo
Trial: 31403610
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g·d for 7 days)
Trial: 26888096
Drug: Para (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Para (1000 mg paracetamol)
Trial: 26888096
Drug: Para‐Caf (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Para‐Caf (1000 mg paracetamol/130 mg caffeine)
Trial: 23856296
Drug: AZD3480 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 50 mg
Trial: 15752944
Drug: ACEi (Angiotensin-Converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEi (Angiotensin-Converting Enzyme Inhibitor)
Trial: 15752944
Drug: ARB (Angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (Angiotensin II Receptor Blocker)
Trial: 29445269
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin oral controlled absorption system (OCAS)
Trial: 29445269
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin OCAS
Trial: 23470848
Drug: Trivalent influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent influenza vaccines (TIV)
Trial: 21707573
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate shampoo 0.05% (CP) twice weekly alternating with ketoconazole shampoo 2% (KC) twice weekly
Trial: 21707573
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate shampoo 0.05% (CP) twice weekly (C2)
Trial: 21707573
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate shampoo 0.05% (CP) four times weekly alternating with ketoconazole shampoo 2% (KC) twice weekly (C4+K2)
Trial: 21707573
Drug: Ketoconazole shampoo
RxNorm normalized name: ketoconazole Shampoo Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole shampoo 2% (KC) twice weekly (K2)
Trial: 27010377
Drug: r‐TMS at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐TMS at frequencies of 5 Hz and 10 Hz for 15 minutes daily for 20 days combined with standard therapy (ST) of 1 hour daily.
Trial: 27010377
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ST) of 1 hour daily for 20 days.
Trial: 22464340
Drug: Biological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological treatment (additional infliximab)
Trial: 22464340
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (additional sulfasalazine and hydroxychloroquine)
Trial: 14736626
Drug: Face-to-face delivered
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face delivered treatment
Trial: 14736626
Drug: Booklet delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booklet delivered treatment
Trial: 1343377
Drug: Silymarin (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (280 mg/day)
Trial: 3905343
Drug: 5 mg/ml
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/ml anhydrous theophylline dissolved in 20% pure alcohol, loading dose of 5 mg/kg and then 1.25 mg/kg every 6 h
Trial: 31370751
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine (group L, n = 40)
Trial: 22684154
Drug: Minimally-invasive surfactant
RxNorm normalized name: surfactant protein-D homotrimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally-invasive surfactant therapy (MIST)
Trial: 21675494
Drug: Doxepin cream
RxNorm normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin cream 5%
Trial: 18988089
Drug: Betamethasone cream
RxNorm normalized name: Betamethasone Cream
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone cream 0.1%
Trial: 19704057
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR 30 mg intramuscularly in monthly intervals
Trial: 12630026
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose hepatitis B virus vaccination (40 mcg) with a shortened immunization schedule
Trial: 7694528
Drug: Desflurane anesthesia
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane anesthesia with epinephrine doses of 7.0-13.0 micrograms/kg
Trial: 7694528
Drug: Isoflurane anesthesia
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane anesthesia with epinephrine doses of 7.0-13.0 micrograms/kg
Trial: 7694528
Drug: Both anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both anesthetic groups with epinephrine doses less than 7.0 micrograms/kg
Trial: 4053529
Drug: Sodium diclofenac
RxNorm normalized name: Diclofenac Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium diclofenac (100 mg tablets of slow-release diclofenac)